Short answer
IDEAYA Biosciences, Inc. (IDYA) filed its Q1 2026 10-Q quarterly report on May 5, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $7M with net income of −$99M.
Q1 2026 key financials · XBRL
- Revenue
- $7M
- Net income
- −$99M
- −36.5% YoY
- Operating margin
- -1654.6%
- EPS (diluted)
- −$1.11
- −35.4% YoY
Source: XBRL data from the IDEAYA Biosciences, Inc. (IDYA) Q1 2026 10-Q on SEC EDGAR. USD.
IDEAYA Biosciences, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Collaboration revenue $6.6M, versus $0 YoY, entirely from Servier agreement
- Net loss $98.5M vs $72.2M YoY; operating loss $(108.5)M vs $(84.4)M
- Highest program spend darovasertib $23.3M; fastest increase IDE034, $6.8M vs $0.04M YoY
- Cash, equivalents and marketable securities $972.9M at March 31, 2026; no ATM share sales
- Cash expected to fund planned operations at least 12 months; continued losses and additional capital needs expected
Risk Factors
- No Risk Factors section provided in the submitted filing text
- No newly added or materially updated risk identifiable from the provided excerpt
- Second lease amendment dated March 20, 2026, indicating a potential occupancy commitment change
- No regulatory, legal, operational, competitive, market, liquidity, debt, currency, or concentration risks disclosed in the excerpt
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other IDEAYA Biosciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.